None listed
Conditions
Brief summary
The long-term aim of this research is to develop a safe, effective and economical program that uses dexamphetamine to assist individuals in the establishment of a healthy pattern of diet and exercise for the treatment of obesity and maintenance of weight control.
Interventions
6 months treatment with oral dexamphetamine, starting at 5mg twice daily and increased if tolerated to 30mg twice daily in weekly increments of 5mg per dose. Compliance will be monitored by keeping track of the amount of medication prescribed and the expected number of tablets used per day.
Sponsors
Nepean Hospital
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
BMI greater than 30 and either obstructive sleep apnoea on PAP or Type 2 diabetes mellitus
Exclusion criteria
History of addiction to illicit drugs, uncontrolled hypertension greater than 140/90, symptomatic ischaemic heart disease, significant kidney or liver disease, uncontrolled epilepsy, weight change of more than 3kg the past 3 months, breastfeeding, pregnant or planning pregnancy, history of bariatric surgery, current depression or other psychiatric illness, current treatment with psychotropic medication, systemic glucocorticoids or medication for weight loss (eg orlistat), family history of sudden death from cardiac causes, hypersensitivity to dexamphetamine or any components of the tablet.
Outcome results
None listed